Prescient Therapeutics Limited
ASX: PTX.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James McDonnell
- Employees
- 3
- Headquarters
- Melbourne, Australia
- IPO year
- 1999
- Market cap
- A$56.8M
- Website
- https://ptxtherapeutics.com
Loading PTX…
Loading profile data…Frequently asked questions about PTX
What does Prescient Therapeutics Limited (PTX.AX) do?
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent plati...
Where does PTX.AX trade?
Prescient Therapeutics Limited (PTX.AX) trades on the Australian Securities Exchange.
What sector is PTX.AX in?
Prescient Therapeutics Limited (PTX.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Prescient Therapeutics Limited?
James McDonnell is the chief executive officer of Prescient Therapeutics Limited (PTX.AX).
Where is Prescient Therapeutics Limited headquartered?
Prescient Therapeutics Limited is headquartered in Australia.
Does PTX.AX pay a dividend?
Prescient Therapeutics Limited (PTX.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PTX.AX go public?
Prescient Therapeutics Limited (PTX.AX) completed its initial public offering in 1999.